A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

CLEVER-1 is a scavenger receptor expressed in tumour associated macrophages. We worked with Faron Pharmaceuticals on this trial, designed to assess the safety and preliminary efficacy of FP-1305 in patients with advanced solid tumours. It showed that the compound promotes immune switch and peripheral lymphocyte activation and has promising tolerability.

Back to Clinical Trial Publications Archive